According to the Market Statsville Group (MSG), the global infliximab market size is expected to grow at a CAGR of 11.3% from 2023 to 2033. The increasing prevalence of inflammatory diseases such as Crohn's disease and ulcerative colitis are major driving factors for the infliximab market. For instance, according to Crohn's and Colitis Foundation, approximately 3 million...